by emma
17. October 2011 17:01
US-based orthobiologics company ISTO Technologies has received CE Mark Approval to market its InQu product line, a bone graft substitute and extender, in the EU.
The product is designed for use in non-structural areas of bone, such as small voids from benign tumour excisions.
Dr Mitchell Seyedin, President and CEO of ISTO, said: “The product has proven to be an innovative and cost-effective bone grafting alternative for spinal fusion and other orthopaedic surgeries in the United States and we believe that distribution in Europe will augment our domestic revenue growth.”
InQu is a differentiated biomaterial scaffold of synthetic and biologic polymers used mainly in spinal fusion applications.
Dr Seyedin said that the approval will “offer a great alternative for patients in need of bone grafting”.
Based in Missouri, ISTO is an orthobiologics company that develops proprietary products for spinal therapies and sport medicine applications. The company’s products are intended for the repair and regeneration of damaged or injured cartilage and bone.
b27127e8-2f3f-4d05-b821-afe6eb6072d8|0|.0
Tags: bone graft, product, EU, approval, CE Mark approval, Europe, ISTO Technologies, US, USA, market, InQu, product line, bone graft substitute, extender, non structural, bone, benign tumour, excisions, Mitchell Seyedin, President, CEO, ISTO, cost effective, price, spend, innovative, alternative, spinal fusion, biomaterial, scaffold, synthetic, biologic, Missouri, spinal therapies, sport medicine, company, products, repair, regeneration, damaged, injured, cartiledge, treatment, therapy
Medtech News
Subscribe